KARACHI: In a big move from AGP Limited on Friday, the company has been able to secure board approval for the merger of its pharma companies, thereby integrating its four affiliated pharma firms under one platform. The pharma merger by AGP Limited aims at generating revenues of about Rs37.5 billion, which would amount to an addition of about Rs8.7 billion over its standalone figure, while also expecting its profits to touch Rs5.6 billion.
The Board of Directors discussed the matter in three different meetings on May 15, May 20, and May 22, 2026. Following that, the Board decided to accept the arrangement and notified the same to the Pakistan Stock Exchange.
Four Entities, One Unified Platform
The merger of AGP Limited in the pharma sector involves integration of five different companies in one newly structured platform. The OBS AGP (Private) Limited with the Sandoz portfolio merges into AGP Limited, while OBS Pakistan (Private) Limited with the Viatris portfolio merges into AGP Limited. The OBS Pharma (Private) Limited with the Bayer portfolio merges into AGP Limited after a demerger.
Combined, these companies possess a portfolio of therapeutic products ranging from gynecology, consumer healthcare, dermatology to pharmaceuticals. The merger of these companies will provide the new AGP Limited company with an extensive range of pharmaceutical products than any single company individually.
From Position 15 to Top 10 – A Shift in Rankings That the Market Cannot Ignore
The most important commercial benefit of the merger between AGP Limited and its competitors in the pharmaceutical business is perhaps their market ranking. AGP Limited is currently ranked 15th among all the other pharmaceutical firms in Pakistan. The newly-formed company will be ranked amongst the top 10 pharmaceutical firms in Pakistan – a huge shift in their market ranking.
This increased ranking will be of tremendous commercial advantage too. A top 10 ranking position in the pharmaceutical industry in Pakistan normally leads to better distributor connections, more leverage while negotiating with hospital committees, and heightened visibility for physicians.
Shareholders Have Potential for 10.5% Earnings Enhancement
The acquisition by AGP Limited offers a tangible gain to the current shareholders of AGP Limited – that is an earnings enhancement potential of approximately 10.5%. This provides the current shareholders with justification to vote positively on the special resolution necessary for the deal to proceed.
To complete the merger, AGP intends to offer 22.015 million shares to OBS AGP Shareholders, 2.736 million shares to OBS Pakistan Shareholders, and 91.39 million shares to OBS Pharma Shareholders using the agreed swap ratio. This distribution of the share issuance is based on the size and value of their respective portfolios within the consolidated platform.
ALSO READ: Pakistan Stock Market Soars 2,248 Points as Trump’s Iran Strike Pause Sparks Historic Rally
AGP Manufacturing Plants Increase to Four
Apart from the financial gains and increased rank, the AGP Limited pharma merger is one that increases AGP Limited’s physical manufacturing plant capacity. Currently, AGP has three manufacturing plants, and this merger brings with it a fourth one, which specializes in manufacturing hormones and psychoactive drugs. This plant occupies three acres of land in Quaid-e-Azam Industrial Estate, Lahore.
It is the fourth plant that brings the overall platform strength in the manufacturing capabilities associated with areas that have strong clinical and regulatory demands, and manufacturing capabilities will act as competitive hurdles which will not be easily replicated by generics.
Brand Portfolio and Regulatory Approaches Going Forward
As a result of the AGP Limited merger in the pharma industry, there is an enhanced brand portfolio, consisting of products such as Ciproxin, Primolut N, Gravibinan, Travocort, Travogen, Skinoren, Noctamid, Testoviron, and Utrogestan – well-known pharmaceutical brands in various treatment classes.
The entire process takes place in accordance with Section 279 through 283 and Section 285(8) of the Companies Act, 2017, which demands approval from shareholders and creditors along with other legal formalities before implementation. It is necessary for the entire process of approval of this merger process, since each phase of approval involves time on its own.
